特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒトマイクロバイオームの世界市場:成長機会・市場予測 (~2023年)

Growth Opportunities in Human Microbiome Market, Forecast to 2023

発行 Frost & Sullivan 商品コード 916767
出版日 ページ情報 英文 88 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
ヒトマイクロバイオームの世界市場:成長機会・市場予測 (~2023年) Growth Opportunities in Human Microbiome Market, Forecast to 2023
出版日: 2019年11月06日 ページ情報: 英文 88 Pages
概要

当レポートでは、ヒトマイクロバイオームを用いたOTC製品・治療薬・診断薬の市場を調査し、市場の定義と概要、市場動向・市場成長への各種影響因子の分析、主要課題、関連法規制シナリオ、収益予測、パイプラインの動向、競合環境、主要企業の取り組み、成長機会・成功戦略の分析などをまとめています。

エグゼクティブダッシュボード

市場概要

  • 市場の定義
  • マイクロバイオーム治療薬:主なタイプ
  • 主要イニチアチブ
  • 推進因子と障壁
  • 推進因子と障壁:影響マッピング

市場力学

  • 主要課題
  • マイクロバイオームの導入に大きな影響を与える領域
  • 法規制シナリオ分析:OTC部門
  • 法規制シナリオ分析:マイクロバイオーム医薬品

成長環境:ヒトマイクロバイオーム市場

  • マーケットエンジニアリング測定
  • 予測の前提因子
  • 収益予測
  • 収益予測:部門別
  • パイプライン分析
  • 注目のマイクロバイオーム医薬品

競合環境

  • ベンダー エコシステム
  • 注目の企業:Enterome Bioscience
  • 注目の企業:Chr. Hansen
  • 注目の企業:Seres Therapeutics
  • 注目の企業:Viome
  • その他の注目企業:マイクロバイオーム治療薬
  • その他の注目企業:マイクロバイオーム診断薬
  • 大手医薬品事業者の支出分析
  • ライセンシング契約の分析
  • 主要企業:注力領域・候補薬の開発ステージ

ビジョニングシナリオ

  • マクロからミクロへのビジョニング
  • 将来の動向

成長パイプライン

  • 成長レバー

成長機会・戦略 - 実装・提言:ビジョン・戦略

  • 成長機会:マイクロバイオームベースの癌免疫治療薬
  • 成長機会:マイクロバイオームコンパニオン診断によるパーソナライズドメディシン (個別化医療)

成長機会・戦略 - 実装・提言:ブランド・需要

  • 成長機会:ウェルネス・DTCMTによるデータ収益化
  • 成長機会:マイクロバイオーム (OTC製品・医薬品) 受託製造
  • 成長機会マトリックス
  • ヒトマイクロバイオーム企業の焦点地域
  • 将来の主な治療領域
  • ヒトマイクロバイオーム企業の戦略的必須要件

総論

付録

目次
Product Code: MECA-55

Strategic Collaborations and Stakeholder Awareness Along with Clear Paths to Commercialization will Play a Key Role for Success in the Human Microbiome Market

Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulation, but the importance of therapeutic and diagnostic products is rapidly increasing with more research substantiating the potential of microbiome-based therapy. Diagnostic applications of the microbiome include the diagnosis of infections and monitoring of microbial components related to non-communicable, chronic diseases.

The effect of next-generation sequencing (NGS) and the disruptive response to genomics has resulted in the development of novel, biomarker-based diagnostics and screening tests that only detect microbiome interactions or presence in humans. These are either direct-to-consumer products for more robust evaluations.

Because microbiome-based therapies constitute an entirely new therapeutic category, there is much uncertainty about the best paths to commercialization The United States is expected to have a faster adoption due to higher interest and awareness generated in this field by the Food and Drug Administration (FDA). One of the critical challenges in microbiome research is deciding whether a particular change in the microbiota is accountable for a specific condition, or if it is a side effect. The complexity of the microbiome and the fact that each person has a distinct one makes it extremely difficult to determine cause-effect relationships.

The global demand for more effective medicines and healthier nutrition will continue to drive the development of microbiomic products. Advancements in genomic sequencing and computer algorithms are expected to create both medicines and therapeutics based on individual microbiomes for better outcomes and healthier lives that will prevent or minimize diseases.

Research Highlights:

This study highlights the growth opportunities, visioning scenarios, innovative business models/use cases, competitive landscape, and key drivers and restraints, along with a revenue forecast for the human microbiome market.

Key Issues Addressed:

  • What is the market size and growth forecast for the human microbiome segments?
  • Who are the key competitors in this market? How does the competitive landscape look like?
  • What are the key growth opportunities for existing companies and new entrants in this market?
  • What changes to the business model are required from companies to cater to changes in market conditions?
  • How is the human microbiome market evolving? What are the key partnerships and collaborations in this industry?
  • What are the strategic imperatives for human microbiome industry participants?

Table of Contents

Executive Dashboard

  • Purpose of this Experiential Study
  • 5-Step Process to Transformational Growth
  • Market Scope and Segmentation
  • Key Questions this Study will Answer
  • Market Snapshot
  • Market Engineering Measurements-Human Microbiome Market
  • Key Findings
  • Frost & Sullivan's Big Market Prospects
  • Major Growth Opportunities
  • Microbiome Ecosystem-Industry Convergence Map
  • Strategic Imperatives for Growth

Market Overview

  • Market Definition
  • Key Types of Microbiome Therapeutics
  • Understanding Human Microbiome-Major Initiatives
  • Understanding Human Microbiome-Major Initiatives (continued)
  • Drivers and Restraints
  • Impact Mapping of Drivers and Restraints

Market Dynamics

  • Key Challenges in the Human Microbiome Market
  • Areas That Will Highly Impact Microbiome Adoption
  • Regulatory Scenario Assessment-OTC Segment
  • Regulatory Scenario Assessment-OTC Segment (continued)
  • Regulatory Scenario Assessment-Microbiome-based Drugs
  • Regulatory Scenario Assessment-Microbiome-based Drugs (continued)
  • Regulatory Scenario Assessment-Microbiome-based Drugs (continued)

Growth Environment-Human Microbiome Market

  • Market Engineering Measurements-Human Microbiome Market
  • Forecast Assumptions
  • Revenue Forecast
  • Forecast Discussions
  • Revenue Forecast by Segment
  • Microbiome-based Drugs-Pipeline Analysis
  • Microbiome-based Drugs-Pipeline Analysis (continued)
  • Microbiome-based Drugs-Pipeline Analysis (continued)
  • Key Microbiome-based Drugs to Watch

Competitive Landscape

  • Vendor Ecosystem
  • Key Companies to Watch-Enterome Bioscience
  • Key Companies to Watch-Chr. Hansen
  • Key Companies to Watch-Seres Therapeutics
  • Key Companies to Watch-Viome
  • Other Companies to Watch-Microbiome Therapeutics
  • Other Companies to Watch-Microbiome Diagnostics
  • Analysis of Big Pharma Spend on Human Microbiome Market
  • Analysis of Big Pharma Spend on Human Microbiome Market (continued)
  • Key Licensing Deals Analysis
  • Key Licensing Deals Analysis (continued)
  • Key Licensing Deals Analysis (continued)
  • Key Companies by Therapeutic Area of Focus and Stage of Microbiome Therapeutic Candidate

Visioning Scenarios

  • Human Microbiome Market-Macro to Micro Visioning
  • Key Future Trends in the Human Microbiome Market

Growth Pipeline

  • Levers for Growth

Growth Opportunities, Strategies-Implementation and Recommendation: Vision and Strategy

  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies
  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies (continued)
  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies (continued)
  • Growth Opportunity 1-Microbiome-based Cancer Immunotherapies (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)
  • Growth Opportunity 2-Personalized Medicine Through Microbiome Companion Diagnostics (continued)

Growth Opportunities, Strategies-Implementation and Recommendation: Brand and Demand

  • Growth Opportunity 3-Wellness and Data Monetization Through DTCMT
  • Growth Opportunity 3-Wellness and Data Monetization Through DTCMT (continued)
  • Growth Opportunity 4-Microbiome (OTC and Therapeutic) Contract Manufacturing
  • Growth Opportunity 4-Microbiome (OTC and Therapeutic) Contract Manufacturing (continued)
  • Growth Opportunity Matrix
  • Focus Geographies for Human Microbiome Companies
  • Key Therapeutic Areas to Look Out for in Future
  • Strategic Imperatives for Human Microbiome Companies

The Last Word

  • 3 Big Predictions
  • Legal Disclaimer

Appendix

  • Research Till Date Has Identified Broadly 9 Therapy Areas Which Includes Multiple Chronic Diseases
  • List of Exhibits
  • List of Exhibits (continued)